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Abstract
The pathophysiology of neurodegeneration in the central nervous system is complex 
and multifactorial in nature and yet to be fully understood. Broad-spectrum neuro-
protective agents with multiple mechanisms of action rather than a single druggable 
target are, therefore, highly desirable. The main human estrogen, 17β-estradiol, can 
also be considered a neurosteroid as it forms de novo in the central nervous system, 
and it possesses beneficial effects against practically all critical contributors to neu-
rodegeneration to collectively thwart both the initiation and the progression of neu-
ronal cell death. This chapter details the main aspects of the hormone’s genomic and 
non-genomic actions important to protect the highly vulnerably neurons of the central 
nervous system, as well as translational efforts to successfully realize its powerful neu-
roprotective potential in clinical setting while ensuring both therapeutic safety and 
efficacy.
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1. Introduction
The steroid hormone 17β-estradiol (E2, Figure 1) is the main human estrogen that is not only 
involved in sexual maturation and reproduction but also has a myriad of important roles 
throughout the body affecting, for example, the cardiovascular system, lipid metabolism and 
brain health [1–4]. Therefore, E2 cannot only be considered as just a “female hormone.” In 
humans, the other two endogenously formed estrogens are estrone (E1, Figure 1) and the 
lesser-known estriol (E3, Figure 1) that is the 16-hydroxy derivate of E2 and formed mostly 
during gestation by the placenta. E1 becomes the predominant estrogen in women after 
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menopause, when it is synthesized largely in subcutaneous fat from androstenedione. The 
unique structure of estrogens among steroids arises from the presence of the aromatic A-ring 
(Figure 1).
E2 is now also considered as one of the neurosteroids, as its regioselective local formation in 
the brain has been established [5–8]. Indeed, with today’s modern analytical instrumentations 
and using validated bioassays that are devoid of the limitations of immunoassays [9], brain 
E2 level even in ovariectomized animals (i.e., in animals without gonadal E2 source) can be 
measured [10, 11]. It has been hypothesized that this de novo central formation of E2 due to the 
lack of gonadal E2 sources, for example, as in case of ovariectomy, is essentially a compensa-
tory mechanism to protect the estrogen-deprived brain that cannot receive the hormone from 
the circulation any more, although plasma estrogen levels do not directly correlate with that 
of brain [12, 13]. Additionally, de novo synthesis of E2 with a presumed role of neuroprotection 
in the developing mammalian brain has also been shown [14].
Independent of the loci of estrogen’s gonadal or extra-gonadal biosynthesis from cholesterol 
via a number of enzyme-catalyzed steps, the final process is the oxidation of the 10-methyl 
group of testosterone, followed by elimination and subsequent aromatization into E2 by aro-
matase. This step is the one that has been controlled by aromatase inhibitors in clinical prac-
tice to prevent the reoccurrence of estrogen-dependent malignancies [15].
Among estrogens and estrogenic compounds, E2 also is the best-known estrogen to be used 
as a powerful neuroprotective agent in various in vitro and preclinical animal models of 
neurodegeneration impacting the central nervous system (CNS) [16–20]. It is important to 
emphasize, though, that E2 has a large array of other beneficial effects in the CNS, including 
regulating body temperature, enhancing cognition and memory and ameliorating neuropsy-
chiatric conditions in both females and males [7, 11, 21–23]. While the brain is undoubtedly 
the most frequently studied part of the CNS in the context of neuroprotection [24–26], the 
utility of E2 in protecting the eye (retina and optic nerve) [27–29] and spinal cord [30–32] have 
also been explored with promising outcomes.
Altogether, extensive basic science investigations brought about convincing data on the pleth-
ora of mechanisms by which E2 promotes neuronal survival and protects neurons against a 
wide variety of stressors addressing, thereby, practically all proposed critical contributors 
to neurodegeneration such as inflammation, oxidative stress, excitotoxicity and collapse of 
mitochondrial membrane potential. Clinical and epidemiological observations also suggest 
that in humans the better outcome after neurotrauma (e.g., traumatic brain and spinal cord 
injuries) in premenopausal females compared with age-matched men, at least in part, is due 
to the protective role of endogenous estrogens against neuronal injuries [33, 34].
Figure 1. Chemical structure of human estrogens: estrone (E1), 17β-estradiol (E2) and estriol (E3).
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2. Mechanistic overview of neuroprotection by estrogens
The broad-spectrum protective mechanism of E2 on injured neurons is the end result of well-
orchestrated and synergistic combination of genomic and non-genomic actions of the hor-
mone that allows for prevention of both the initiation and progression of neuronal cell death. 
This implicates a significant translational value for the hormone upon restricting its action to 
the CNS, as detailed in the following section.
2.1. Genomic pathways in E2 neuroprotection
Estrogen receptors (ERs) are expressed throughout the brain [35, 36] indicating their role in 
various CNS functions including neuroprotection. ER density is higher in the hypothala-
mus than in extrahypothalamic areas with overlapping expression of the two isoforms ERα 
and ERβ [35, 36]. In some brain regions, ERα or ERβ may also be co-localized in cells [37]. 
However, ERβ is highly expressed in the cortex [38] and hippocampus [39, 40]. Consequently, 
estrogen impacts the function of extrahypothalamic areas that are not involved in sex matura-
tion and reproduction [41].
The two ERs have similar affinities to endogenous estrogens [42]. Just like many other mem-
bers of the nuclear receptor superfamily of proteins, they elicit their genomic effect through 
gene transcription [43]. The sequence of the classical ligand-dependent genomic mechanism of 
estrogens’ neuroprotective action is summarized in Figure 2. After E2 (or in general, an estro-
gen) distributes into the neuron and reaches the nucleus, it is ligated to its cognate receptor. The 
ligated ERs form homo- (ERα/ERα or ERβ/ERβ) or heterodimers (ERα/ERβ) that bind to the 
estrogen-response element (ERE) of the nuclear DNA. Transcriptional activation is enabled by 
Figure 2. A simplified model for the ligand-dependent genomic mechanism of E2 neuroprotection. After E2 distributes 
into the neuron (A) and enters the nucleus, it binds to the cognate receptor followed by dimerization of the ligated ER 
that binds, together with co-regulators, to the nuclear DNA’s ERE, which results in the transcription of the corresponding 
gene (B). E2, ER, co-regulator (Co-r) and the nuclear DNA are symbolized by the filled steroid shape, rounded rectangles 
and elongated rectangle showing an ERE (shaded area), respectively.
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a constitutively active and a ligand-dependent function located at the amino-terminus and in 
the carboxy-terminal ligand-binding domain of ERs, respectively [44]. The DNA-bound dimers 
recruit co-regulator proteins [45], which can participate in and also recruit many enzymatic 
and structural proteins permitting the modulation of chromatin structure to facilitate or block 
gene expression [46]. Additionally, ERE-independent mechanisms have also been shown [47].
Neuroprotective target genes for E2 that directly support vital neuronal functions include neu-
rotrophic factors such as the brain-derived neurotrophic factor [48]. Additional target genes are 
involved in apoptosis to remove unneeded, damaged or potentially deleterious cells [49] play-
ing thereby a central role in development and homeostasis. Through the apoptosis-associated 
genomic mechanism, E2 has been shown to rescue neurons through the induction of anti-apop-
totic proteins such as Bcl-2 [50] or suppression of apoptotic proteins such as the Bcl-2-associated 
X protein [50, 51]. Induction of several gene products that maintain cellular architecture such as 
neurofilament, tau and microtubulin-associated proteins and many additional genomic path-
ways potentially associated with E2’s neuroprotection have also been described [52].
2.2. Modulation of intracellular signaling by E2
E2 also rapidly induces numerous cellular responses, which cannot be explained by a delayed 
genomic effect. ERs have been shown to be present in membrane compartments and in the 
cytoplasm [53, 54]. Specifically, ERα and ERβ are also found as homo or heterodimers at the 
cell membrane; they are membrane-associated but not actually embedded in the membrane. 
In addition, a G protein-coupled estrogen receptor (GPER) is localized mainly to intracellular 
membranes, including the endoplasmic reticulum and Golgi apparatus, under steady-state 
conditions [55]. G protein-coupled receptors such as GPER can actually signal from intracel-
lular locations [56] and activation results in intracellular Ca2+-mobilization and synthesis of 
phosphatidylinositol 3,4,5-triphosphate in the nucleus, which could impact gene transcrip-
tion indirectly. The mitogen-activated protein kinase (MAPK) cascade [57] and the cyclic-
AMP-responsive element-binding protein signaling pathway [58, 59] also respond rapidly to 
E2 and have been implicated in its neuroprotective effects.
An E2-ER complex can also function through cytoplasmic signaling to provide neuroprotec-
tion [60]. For example, ERs have been shown to bind in a ligand-dependent manner to the p85 
alpha regulatory subunit of phosphatidylinositol 3-kinase (PI3K) [61, 62]. Therefore, stimula-
tion with E2 increases ER-associated PI3K activity, leading to the activation of protein kinase 
B/Akt and endothelial nitric oxide synthase. However, modulation of intracellular pathways 
may occur though the binding of E2 to ERs, or independently of ligand binding [63, 64]. A 
representative of the non-genomic mechanism involving the modulation of intracellular sig-
naling through ERs is summarized schematically in Figure 3.
E2 has been proposed to influence neurotransmission directly by binding to various trans-
membrane ion channels [65, 66]. Localization of ERβ to the mitochondria has also been shown 
[67], implicating E2 in the regulation of mitochondrial structure and function in the brain [68]. 
In addition to estrogen potentially influencing bioenergetics through long-lasting nuclear-
associated processes, rapid mitochondria-intrinsic signaling mechanisms that promote the 
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maintenance of this organelle’s integrity could contribute therefore to the neuroprotective action 
of E2. Essentially, the hormone could minimize mitochondrial dysfunctions, which accom-
pany neurotrauma, aging and neurodegenerative diseases [69]. However, continued research 
is needed to fully understand molecular details about the apparently complex interactions 
between ERs and cellular signaling pathways in the context of neuroprotective mechanisms.
2.3. Anti-inflammatory action
The influence of E2 on neuroinflammation, a process commonly accompanying neurotrauma 
and neurodegenerative diseases [70–72], has been well established. Direct action on microglia 
and astrocytes (the cellular component of the neuroimmune system) and response to periph-
eral blood cells’ infiltration to the brain have been implicated as major contributors to the 
observed anti-inflammatory action of the hormone often impacting the cerebral vasculature 
[73, 74]. For example, E2 can suppress chemokine-mediated induction of the cyclooxygen-
ase-2 (COX-2) pathway in cerebral blood vessels thereby preventing migration of microglia 
into the brain after an inflammatory challenge [75]. Although inflammatory processes in the 
brain are usually associated with microglia and astrocytes, expression of the COX-2 gene in 
neurons and possible mechanisms by which E2 down-regulates this inflammation-associated 
gene have been shown recently [76]. Specifically, ERβ contributes to neuronal expression of 
COX-2, and E2 leads to increased recruitment of histone deacetylase 1 (HDAC1), switch-inde-
pendent 3A (Sin3A) and a concomitant reduction of nuclear factor-κ B (NF-κ B) p65 occupancy 
and histone 4 acetylation levels. The hormone also prevents the activation of microglia and 
the recruitment of peripheral monocytes induced by a toxic stimulus. This effect involves ERα 
activation and reduces the expression of pro-inflammatory mediators and E2 have also shown 
to prevent morphological changes occurring in microglia during inflammatory response [77]. 
Decrease of microglial superoxide production and phagocytic activity by both an ER- and 
Figure 3. An example of non-genomic action of E2 involving interaction with intracellular signaling pathways through 
ERs. As in Figure 2, E2, ER and the nuclear DNA are represented by the filled steroid shapes, rounded rectangles and 
elongated rectangle indicating a regulated gene promoter (shaded area), respectively, while the ER-interacting protein 
(↔) such as PI3K is shown by a shaded oval.
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MAPK-dependent pathway have also been reported among the anti-inflammatory effects of 
E2 [78]. In addition, the hormone inhibits pro-inflammatory gene expression by controlling 
intracellular localization of NF-κ B [79].
2.4. Antioxidant effects
Oxidative stress-induced damage has been linked to brain aging [80], neurodegenerative 
diseases [81] and neurotrauma [25, 26]. From a long time, therapeutic antioxidant interven-
tions have been proposed to reduce the detrimental impact of oxidative stress [82]. E2’s 
ER-independent antioxidant effects are mainly due to its ability to attenuate free-radical 
reactions [83], although indirect mechanisms such as up regulation of antioxidant enzymes 
[84, 85] and chelation of redox-active metal ions [86] have been reported. The neuroprotective 
effect of the hormone through direct oxidative stress reduction has been recognized in part 
by structure-activity relationship studies [87–89]. Acute E2 neuroprotection in ischemic brain 
[90] or against damage by ionizing radiation [91] may be largely conferred through antioxi-
dant mechanisms.
The quintessential feature of estrogens as neuroprotective antioxidants is their phenolic 
A-ring [83, 92, 93]. Because of its lipophilicity, E2 concentrates in lipid-rich regions of the cell 
such as cellular membranes [94]. Therefore, it is likely that estrogens act in vivo as a highly 
localized antioxidant [83]. The mechanism of direct oxyradical-scavenging by E2 functioning 
as a phenolic antioxidant is shown schematically in Figure 4.
The process involves H-atom transfer that causes an interruption of free-radical chain reac-
tions, such as lipid peroxidation (R = LOO, where L represents a lipid). Estrogens, indeed, 
reduce lipid peroxidation in cells and tissues of the CNS [95]. However, the chain-breaking 
reaction leaves behind a radical product (phenoxyl radical) whose fate has to be explained in 
consideration of an efficient antioxidant action observed both in vitro and in vivo. Indeed, phe-
nolic antioxidants can be regenerated from the corresponding phenoxyl radicals by a reaction 
with ascorbic acid (vitamin C) [96] or through glutathione-dependent free-radical reductase 
[97]; therefore, a continuous antioxidant cycle is established by E2.
Figure 4. E2’s effect through the classical phenolic antioxidant mechanism. The solid arrows represent the chain-
breaking H-atom transfer, such as lipid peroxidation, while the dashed arrows indicate the conversion of the E2-derived 
phenoxyl radical back to the phenolic compound by an endogenous reductant (AH) such as ascorbic acid or glutathione.
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Our laboratory pioneered in recognizing a complementary novel neuroprotective antioxidant 
cycle that involves a para-quinol as a molecular intermediate of oxyradical scavenging and, then, 
NADPH-mediated enzyme-catalyzed reductive aromatization [98–100] to regenerate E2, as 
shown in Figure 5. We wish to name this previously unrecognized antioxidant cycle for simple 
phenolic antioxidants as the “Prokai antioxidant cycle.” The enzyme activity driving the reduc-
tive phase of the cycle is observed predominantly in neuronal tissue [101]. Beyond its mechanis-
tic significance regarding oxidative stress-reducing effect, this discovery has prompted a strategy 
for brain-selective estrogen therapy using a prodrug approach detailed in the following section.
3. CNS-selective estrogen neurotherapy
The pathophysiology of neurodegeneration in the central nervous system is complex and mul-
tifactorial in nature [102]. Therefore, it is not surprising that an agent like E2 can provide robust 
protection against a myriad of neuronal insults owing to its broad-spectrum activity resulting 
from well-orchestrated genomic and non-genomic actions, as detailed in Section 2. The need 
for clinical therapeutic interventions that can be used to target multiple parallel mechanisms 
of neuronal injury has been repeatedly expressed [101–103]. We argue that, despite profound 
dichotomy between basic science and clinical studies, E2 is ideally suited to be developed as a 
broad-spectrum neuroprotectant if its action can be restricted to the CNS, that is, to the site of 
action to avoid undesirable peripheral hormonal burdens. Since neurotrauma triggers a cas-
cade of biochemical events leading to further damages decreasing thereby the chance of appre-
ciable functional recovery [17, 20, 102, 103], chronic pharmacotherapeutic interventions should 
be considered in the context of translational research. This, on the other hand, brings about crit-
ical considerations for safety and efficacy, which highlights the need for brain-selective (or in 
general CNS-selective) neurotherapy, considering both a preventative and a curative modality.
When estrogen neurotherapy is considered, however, one cannot ignore the (in)famous 
Women’s Health Initiative (WHI) study [104]. This was a placebo-controlled, randomized 
trial of hormone “replacement” therapy in postmenopausal women that indicated detrimen-
tal consequences of estrogen and progesterone supplementations, among others, for brain 
Figure 5. The Prokai antioxidant cycle for E2 through the formation of a para-quinol (10β,17β-dihydroxyestra-1,4-dien-
3-one, DHED) as an intermediate, which is reduced to the parent hormone by enzyme-catalyzed reduction involving 
NADPH as cofactor.
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health, propagating thereby a dogma that all estrogens (and progestins) are “created equal.” 
The fact is that WHI did not use human hormones and, thus, did not study the effect of 
hormone replacement per se in aging women. On the contrary, conjugated equine estrogens 
(CEE) and a synthetic progestin were used for women with intact uterus. CEE is a complex 
mixture of over 60 different estrogens from pregnant mares’ urine, and it only contains a small 
amount of E2: the main constituents are the sulfate esters of B-ring saturated and unsaturated 
estrogens [105]. The pharmacokinetic and toxicology profiles of these non-human estrogens 
are different from those of E2; therefore, direct comparison between E2 and CEE is fundamen-
tally unjustified [106, 107]. Accordingly, the beneficial central effects of E2, including robust 
neuroprotection based on clinical, epidemiological and basic science observations should not 
be undermined in view of the confusion brought about by the WHI studies.
Nevertheless, an E2-based neurotherapy cannot be realized in clinical settings until E2’s actions 
are restricted to the site of action assuring therapeutic safety and efficacy. Currently approved 
E2 dosage forms expose the entire body to the hormone through the circulation, potentially 
leading to detrimental side-effects including cardiovascular problems and the development of 
certain type of cancers upon chronic administration that is required for long-term neuropro-
tection and functional recovery after neurotrauma. Feminization (e.g., gynecomastia) is also a 
critical negative aspect of estrogen therapy, especially in case of children and males.
Early attempts to restrict E2’s actions to the brain upon systemic administration included the 
so-called chemical delivery system, which was conceptually a complex prodrug approach 
carrying a 1,4-dihydrotrigonellyl promoiety and is capable to usher the hormone through the 
blood brain barrier (BBB). Once in the brain, the prodrug is oxidized analogously to that of 
NADP(H) ⇌ NADP+, locking thereby the oxidized prodrug into the brain before it releases 
E2 [108]. This approach does result in significantly increased brain-enhanced delivery of the 
hormone compared to that of simple prodrugs of E2; however, it still results in sufficient 
increase in circulating E2 that can produce unwanted peripheral hormonal burdens [10, 109]. 
Prodrugs are inert precursors of their corresponding biologically active parent drugs and they 
traditionally carry auxiliary bioreversible “promoiety(ies)” that are removed enzymatically 
(rarely via chemical reaction, such as pH-dependent hydrolysis) in the body [108].
An important development in achieving a true CNS-selective estrogen therapy has been 
achieved by our laboratory [101] and was derived from our previous discovery of a novel 
antioxidant cycle for estrogens we call the Prokai antioxidant cycle for simple phenolic anti-
oxidants [98–100], and detailed in Section 2. We recognized that 10β,17β-dihydroxyestra-1,4-
dien-3-one (DHED, Figures 5 and 6), which is chemically a para-quinol (not to be mistaken 
for quinones involved in E2-induced carcinogenesis through redox cycling [99]), can be 
reductively rearomatized to the parent E2 and, thus, could serve as a bioprecursor prodrug 
for E2. The lesser-known bioprecursor prodrugs do not carry auxiliary promoiety(ies) [108] 
because the bioreversible chemical manipulation is carried out within the drug molecule itself 
[101, 110]. Therefore, creation of bioprecursor prodrugs, such as DHED, requires significantly 
greater innovation than that of simple prodrugs; moreover, potential toxicity issues that may 
arise from the release of the “promoity(ies)” from simple prodrugs is eliminated with bio-
precursor prodrugs. Indeed, we have established that CNS-specific and NADPH-dependent 
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dehydrogenase/reductase metabolized DHED to E2 (Figure 6), while prodrug activation did 
not occur in the periphery. This is an unprecedented and distinguishing feature of DHED 
in the context of translational research [101]. With a series of in vitro and in vivo studies, we 
showed that with DHED, for the first time, E2’s actions can be restricted to the brain indepen-
dently of the route and duration of DHED administration and, therefore, it can be used (at 
least in preclinical settings) for the efficacious treatment of estrogen-responsive and centrally 
regulated maladies and injuries, including neurodegeneration brought about by ischemic 
stroke, without hormonal burdens for the rest of the body [101].
The transient middle cerebral artery occlusion (tMCAO) model followed by reperfusion is 
one the most frequently used preclinical animal models for testing an agent for its ability 
to act as a neuroprotectant, that is, to reduce infarct volume and aid in functional recovery 
[20, 24, 101, 111]. As Figure 7 shows, a dose-dependent reduction of infarct volumes and neu-
rological deficits was observed in DHED-treated animals. Moreover, about 10-times higher 
systemic E2 (i.e., the parent drug that is formed in the brain from DHED) dose was needed to 
achieve the same neuroprotection indicating the profound ability of the bioprecursor prodrug 
to enter into the brain from the circulation and, then, produce E2 within the brain, and only in 
Figure 6. Schematic illustration of DHED bioprecursor prodrug’s CNS-selective enzymatic metabolism to E2 via an 
NADPH-dependent reductase.
Figure 7. Dose-dependent (A) brain infarct volumes and (B) neurological deficit (ND) scores in rats treated with DHED 
1 h before tMCAO followed by 24-h reperfusion [101]. The control groups received E2 (200 μg/kg, s.c., approximately 
representing ED50, equivalent to 50% of the maximum effect) or vehicle alone. ©Reproduced with permission by the 
American Association for the Advancement of Science.
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the brain. In the context of translational research, it is noteworthy that the capacity to generate 
E2 from DHED is not lost in an injured brain, as neuroprotection was highly preserved post-
stroke and, again, no hormonal exposure to the rest of the body was observed [101].
4. Conclusion
As neurotrauma and neurodegeneration in the CNS are complex and multifactorial in 
nature requiring therefore broad-spectrum therapeutic interventions, E2 is an attractive 
lead agent to address unmet medical needs in this field. The powerful antioxidant action 
of E2 against oxidative stress owing to its phenolic A-ring is unique among neurosteroids 
with potential neuroprotective roles; therefore, non-genomic mechanisms contribute sig-
nificantly to the overall neuroprotection. This chapter presented an overview of our current 
knowledge on the well-orchestrated genomic and non-genomic events by which E2 could 
beneficially counteract the initiation and/or progression of neuronal cell death. However, 
there has been incongruency between basic science and clinical studies in terms of estrogen 
therapy impacting the brain because most researchers ignore the requirement to confine 
E2’s actions into the CNS upon systemic administration to ensure therapeutic safety and 
efficacy. We highlighted here a novel and unique bioprecursor prodrug approach our labo-
ratory pioneered for brain-selective delivery of E2 without exposing the rest of the body to 
unwanted hormonal burden.
Acknowledgements
The project was supported in part by the National Institutes of Health for the authors, in 
particular grant numbers NS044765, AG031535, MH100700, HD078077 & CA215550 to L.P. 
and AG031421 & EY027005 to K.P.-T. and by the Robert A. Welch Foundation (endowment 
BK-0031 to L.P.).
Conflict of interest
The authors are inventors in the patents covering the use of 10β,17β-dihydroxyestra-1,4-dien-3- 
one (DHED) as a CNS-selective bioprecursor prodrug of 17β-estradiol and are co-founders of 
AgyPharma LLC with equity in the company that licensed the patents.
Author details
Katalin Prokai-Tatrai* and Laszlo Prokai
*Address all correspondence to: katalin.prokai@unthsc.edu
Department of Pharmacology and Neuroscience, University of North Texas Health Science 
Center, Fort Worth, TX, USA
Sex Hormones in Neurodegenerative Processes and Diseases30
References
[1] Turgeon JL, Carr MC, Maki PM, Mendelsohn ME, Wise PM. Complex actions of sex 
steroids in adipose tissue, the cardiovascular system, and brain: Insights from basic sci-
ence and clinical studies. Endocrine Reviews. 2006;27:575-605. DOI: 10.1210/er.2005-0020
[2] Fink G, Sumner BEH, Rosie R, Grace O, Quinn JP. Estrogen control of central neuro-
transmission: Effect on mood, mental state, and memory. Cellular and Molecular Neuro-
biology. 1996;16:325-344. DOI: 10.1007/bf02088099
[3] Mauvais-Jarvis F, Clegg DJ, Hevener AL. The role of estrogens in control of energy 
balance and glucose homeostasis. Endocrine Reviews. 2013;34:309-338. DOI: 10.1210/
er.2012-1055
[4] Gruber CJ, Tschugguel W, Schneeberger C, Huber JC. Production and actions of estro-
gens. New England Journal of Medicine. 2002;346:340-352. DOI: 10.1056/NEJMra000471
[5] Baulieu EE. Neurosteroids: A novel function of the brain. Psychoneuroendocrinology. 
1998;23:963-987
[6] Cui J, Shen Y, Li R. Estrogen synthesis and signaling pathways during aging: From 
periphery to brain. Trends in Molecular Medicine. 2013;19:197-209. DOI: 10.1016/j.
molmed.2012.12.007
[7] Barakat R, Oakley O, Kim H, Jin J, Ko CJ. Extra-gonadal sites of estrogen biosynthesis 
and function. BMB Reports. 2016;49:488-496. DOI: 10.5483/BMBRep.2016.49.9.141
[8] Simpson ER. Sources of estrogen and their importance. Journal of Steroid Biochemistry 
& Molecular Biology. 2003;86:225-230. DOI: 10.1016/S0960-0760(03)00360-1
[9] Stanczyk FZ, Cho MM, Endres DB, Morrison JL, Patel S, Paulson RJ. Limitations of 
direct estradiol and testosterone immunoassay kits. Steroids. 2003;68:1173-1178. DOI: 
10.1016/j.steroids.2003.08.012
[10] Prokai-Tatrai K, Szarka S, Nguyen V, Sahyouni F, Walker C, White S, Talamantes T, 
Prokai L. “All in the mind?” brain-targeting chemical delivery system of 17β-estradiol 
(Estredox) produces significant uterotrophic side effect. Pharmaceutical and Analytical 
Acta. 2013;S7:002. DOI: 10.4172/2153-2435.S7-002
[11] Merchenthaler I, Lane M, Sabnis G, Brodie A, Nguyen V, Prokai L, Prokai-Tatrai K. 
Treatment with an orally bioavailable prodrug of 17β-estradiol alleviates hot flushes 
without hormonal effects in the periphery. Scientific Reports. 2016;6:30721. DOI: 10.1038/
srep30721s
[12] Mc Cullough LD, Blizzard K, Simpson ER, Öz OK, Hurn PD. Aromatase cytochrome 
P450 and extragonadal estrogen play a role in ischemic neuroprotection. Journal of 
Neuroscience. 2003;23:8701-8705
[13] Carswell HV, Dominiczak AF, Garcia-Segura LM, Harada N, Hutchison JB, Macrae IM. 
Brain aromatase expression after experimental stroke: Topography and time course. The 
Journal of Steroid Biochemistry and Molecular Biology. 2005;96:89-91. DOI: 10.1016/j.
jsbmb.2005.02.016
17β-Estradiol as a Neuroprotective Agent
http://dx.doi.org/10.5772/intechopen.72682
31
[14] McCarthy MM. Estradiol and the developing brain. Physiological Reviews. 2008;88:91-
134. DOI: 10.1152/physrev.00010.2007
[15] Behan LA, Amir E, Casper RF. Aromatase inhibitors for prevention of breast cancer in 
postmenopausal women: A narrative review. Menopause. 2015;22:342-350. DOI: 10.1097/
GME.0000000000000426
[16] Tschiffely AE, Schuh RA, Prokai-Tatrai K, Prokai L, Ottinger MA. A comparative evalu-
ation of treatments with 17β-estradiol and its brain-selective prodrug in a double-trans-
genic mouse model of Alzheimer’s disease. Hormons and Behavior. 2016;83:39-44. DOI: 
10.1016/j.yhbeh.2016.05.009
[17] Raghava N, Das BC, Ray SK. Neuroprotective effects of estrogen in CNS injuries: Insights 
from animal models. Neuroscience and Neuroeconomics. 2017;6:15-29. DOI: 10.2147/
NAN.S105134
[18] Zhu Y, Zhang QG, Zhang WL, Li N, Dai YX, Tu JY, Yang F, Brann DW, Wang RM. 
Protective effect of 17beta-estradiol upon hippocampal spine density and cognitive 
function in an animal model of vascular dementia. Scientific Reports. 2017;7:42660. DOI: 
10.1038/srep42660
[19] Fiocchetti M, Ascenzi P, Marino M. Neuroprotective effects of 17β-estradiol rely on 
estrogen receptor membrane initiated signals. Frontiers in Physiology. 2012;3:73. DOI: 
10.3389/fphys.2012.00073
[20] Toung TJK, Traystman RJ, Hurn PD. Estrogen-mediated neuroprotection after experi-
mental stroke in male rats. Stroke. 1998;29:1666-1670. DOI: 10.1161/01.STR.29.8.1666
[21] Gillies GE, McArthur S. Estrogen actions in the brain and the basis for differential 
action in men and women: A case for sex-specific medicines. Pharmacological Reviews. 
2010;62:155-198. DOI: 10.1124/pr.109.002071
[22] Maggi A, Ciana P, Belcredito S, Vegeto E. Estrogens in the nervous system: Mechanisms 
and nonreproductive functions. Annual Review of Physiology. 2004;66:291-313. DOI: 
10.1146/annurev.physiol.66.032802.154945
[23] Cornil CA, Ball GF, Balthazart J. Rapid control of male typical behaviors by brain-
derived estrogens. Frontiers in Neuroendocrinology. 2012;33:425-446. DOI: 10.1016/j.
yfrne.2012.08.003
[24] Carpenter RS, Iwuchukwu I, Hinkson CL, Reitz S, Lee W, Kukino A, Zhang A, Pike MM, 
Ardelta AA. High-dose estrogen treatment at reperfusion reduces lesion volume and 
accelerates recovery of sensorimotor function after experimental ischemic stroke. Brain 
Research. 2016;15:200-213. DOI: 10.1016/j.brainres.2016.01.058
[25] Manzanero S, Santro T, Arumugam TV. Neuronal oxidative stress in acute ischemic 
stroke: Sources and contribution to cell injury. Neurochemistry International. 2013; 
62:712-718. DOI: 10.1016/j.neuint.2012.11.009
Sex Hormones in Neurodegenerative Processes and Diseases32
[26] Cornelius C, Crupi R, Calabrese V, Graziano A, Milone P, Pennisi G, Radak Z, Calabrese EJ, 
Cuzzocrea S. Traumatic brain injury: Oxidative stress and neuroprotection. Antio xidants 
& Redox Signaling. 2013;19:836-853. DOI: 10.1089/ars.2012.4981
[27] Prokai-Tatrai K, Xin H, Nguyen V, Szarka S, Blazics B, Prokai L, Koulen P. 17β-estradiol 
eye drops protect the retinal ganglion cell layer and preserve visual function in an 
in vivo model of glaucoma. Molecular Pharmaceutics. 2013;5:3253-3261. DOI: 10.1021/
mp400313u
[28] Russo R, Cavaliere F, Watanabe C, Nucci C, Bagetta G, Corasaniti MT, Sakurada S, 
Morrone LA. 17β-Estradiol prevents retinal ganglion cell loss induced by acute rise of 
intraocular pressure in rat. Progress in Brain Research. 2008;173:583-590. DOI: 10.1016/
S0079-6123(08)01144-8
[29] Nonaka A, Kiryu J, Tsujikawa A, Yamashiro K, Miyamoto K, Nishiwaki H, Mandai M, 
Honda Y, Ogura Y. Administration of 17β-estradiol attenuates retinal ischemia-reper-
fusion injury in rats. Investigative Ophthalmology & Visual Science. 2000;41:2689-2696
[30] Chaovipoch P, Jelks KA, Gerhold LM, West EJ, Chongthammakun S, Floyd CL. 17beta-
estradiol is protective in spinal cord injury in post- and pre-menopausal rats. Journal of 
Neurotrauma. 2006;23:830-852. DOI: 10.1089/neu.2006.23.830
[31] Samantaray S, Das A, Matzelle DC, Yu SP, Wei L, Varma A, Ray SK, Banik NL. 
Administration of low dose estrogen attenuates persistent inflammation, promotes 
angiogenesis, and improves locomotor function following chronic spinal cord injury in 
rats. Journal of Neurochemistry. 2016;37:604-617. DOI: 10.1111/jnc.13610
[32] Sribnick EA, Samantaray S, Das A, Smith J, Matzelle DD, Ray SK, Banik NL. Postinjury 
estrogen treatment of chronic spinal cord injury improves locomotor function in rats. 
Journal of Neuroscience Research. 2010;88:1738-1750. DOI: 10.1002/jnr.22337
[33] Datto JP, Yang J, Dietrich WD, Pearse DD. Does being female provide a neuroprotective 
advantage following spinal cord injury? Neural Regeneration Research. 2015;10:1533-
1536. DOI: 10.4103/1673-5374.165213
[34] Roof RL, Hall ED. Gender differences in acute CNS trauma and stroke: Neuroprotective 
effects of estrogen and progesterone. Journal of Neurotrauma. 2000;17:367-388
[35] Shughrue PJ, Lane MV, Merchenthaler I. Comparative distribution of estrogen receptor-
alpha and -beta mRNA in the rat central nervous system. Journal of Comparative Neurology. 
1997;388:507-525. DOI: 10.1002/(SICI)1096-9861(19971201)388:4<507::AID-CNE1>3.0.CO;2-6
[36] Shughrue PJ, Scrimo PJ, Merchenthaler I. Estrogen binding and estrogen receptor char-
acterization (ER alpha and ER beta) in the cholinergic neurons of the rat basal forebrain. 
Neuroscience. 2000;96:41-49. DOI: 10.1016/S0306-4522(99)00520-5
[37] Shughrue PJ, Scrimo PJ, Merchenthaler I. Evidence for the colocalization of estrogen 
receptor-beta mRNA and estrogen receptor-alpha immunoreactivity in neurons of the 
rat forebrain. Endocrinology. 1998;139:5267-5270. DOI: 10.1210/endo.139.12.6525
17β-Estradiol as a Neuroprotective Agent
http://dx.doi.org/10.5772/intechopen.72682
33
[38] Zhang JQ, Cai WQ, Zhou DS, Su BY. Distribution and differences of estrogen recep-
tor beta immunoreactivity in the brain of adult male and female rats. Brain Research. 
2002;935:73-80. DOI: 10.1016/S0006-8993(02)02460-5
[39] Milner TA, Ayoola K, Drake CT, Herrick SP, Tabori NE, McEwen BS, Warrier S, Alves 
SE. Ultrastructural localization of estrogen receptor beta immunoreactivity in the rat 
hippocampal formation. The Journal of Comparative Neurology. 2005;491:81-95. DOI: 
10.1002/cne.20724
[40] Mitterling KL, Spencer JL, Dziedzic N, Shenoy S, McCarthy K, Waters EM, McEwen BS, 
Milner TA. Cellular and subcellular localization of estrogen and progestin receptor 
immunoreactivities in the mouse hippocampus. The Journal of Comparative Neurology. 
2010;518:2729-2743. DOI: 10.1002/cne.22361
[41] Hara Y, Waters EM, McEwen BS, Morrison JH. Estrogen effects on cognitive and syn-
aptic health over the lifecourse. Physiological Reviews. 2015;95:785-807. DOI: 10.1152/
physrev.00036.2014
[42] Pike ACW, Brzozowski AM, Hubbard REA. Structural biologist’s view of the oestro-
gen receptor. Journal of Steroidal and Molecular Biochemistry. 2000;74:261-268. DOI: 
10.1016/S0960-0760(00)00102-3
[43] Puzianowska-Kuznicka M, Pawlik-Pachucka E, Owczarz M, Budzinska M, Polosak J. 
Small-molecule hormones: Molecular mechanisms of action. International Journal of 
Endocrinology. 2013;2013:601246. DOI: 10.1155/2013/601246
[44] Nilsson S, Makela S, Treuter E, Tujague M, Thomsen J, Andersson G, Enmark E, 
Pettersson K, Warner M, Gustafsson JA. Mechanisms of estrogen action. Physiological 
Reviews. 2001;81:1535-1565
[45] Tetel MJ, Acharya KD. Nuclear receptor coactivators: Regulators of steroid action in 
brain and behaviour. Journal of Neuroendocrinology. 2013;25:1209-1218. DOI: 10.1111/
jne.12065
[46] Sovell WM. Nucleosome dynamics: HMGB1 facilitates nucleosome restructuring and 
collaborates in estrogen-responsive gene expression. AIMS Genetics. 2016;3:252-279. 
DOI: 10.3934/genet.2016.4.252
[47] Hall JM, Couse JF, Korach KF. The multifaceted mechanisms of estradiol and estrogen 
receptor signaling. Journal of Biological Chemistry. 2001;276:36869-36872. DOI: 10.1074/
jbc.R100029200
[48] Carbone DL, Handa RJ. Sex and stress hormone influences on the expression and activ-
ity of brain-derived neurotrophic factor. Neuroscience. 2013;239:295-303. DOI: 10.1016/j.
neuroscience.2012.10.073
[49] Hail N, Carter BZ, Konopleva M, Andreeff M. Apoptosis effector mechanisms: A requiem 
performed in different keys. Apoptosis. 2006;11:889-904. DOI: 10.1007/s10495-006-6712-8
Sex Hormones in Neurodegenerative Processes and Diseases34
[50] Sharma K, Mehra RD. Long-term administration of estrogen or tamoxifen to ovari-
ectomized rats affords neuroprotection to hippocampal neurons by modulating the 
expression of Bcl-2 and Bax. Brain Research. 2008, 2008;14(1204):1-15. DOI: 10.1016/j.
brainres.2008.01.080
[51] Sribnick EA, Ray SK, Nowak MW, Li L, Banik NL. 17 beta-estradiol attenuates gluta-
mate-induced apoptosis and preserves electrophysiologic function in primary cortical 
neurons. Journal of Neuroscience Research. 2004;76:688-696. DOI: 10.1002/jnr.20124
[52] Segura-Uribe JJ, Pinto-Almazdan R, Coyoy-Salgado A, Fuentes-Venado CE, Guerra-
Araiza C. Effects of estrogen receptor modulators on cytoskeletal proteins in the 
central nervous system. Neural Regeneration Research. 2017;12:1231-1240. DOI: 
10.4103/1673-5374.213536
[53] Levin ER. Extranuclear steroid receptors are essential for steroid hormone actions. 
Annual Review of Medicine. 2015;66:271-280. DOI: 10.1146/annurev-med-050913-021703
[54] Boonyaratanakornkit V. Scaffolding proteins mediating membrane-initiated extra-
nuclear actions of estrogen receptor. Steroids. 2011;76:877-844. DOI: 10.1016/j.steroids. 
2011.02.017
[55] Revankar CM, Cimino DF, Sklar LA, Arterburn JB, Prossnitz ER. A transmembrane 
intracellular estrogen receptor mediates rapid cell signaling. Science. 2005;307:1625-1630
[56] Platta HW, Stenmark H. Endocytosis and signaling. Current Opinion in Cell Biology. 
2011;23:393-403. DOI: 10.1016/j.ceb.2011.03.008
[57] Sawe N, Steinberg G, Zhao H. Dual roles of the MAPK/ERK1/2 cell signaling pathway 
after stroke. Journal of Neuroscience Research. 2008;86:1659-1669. DOI: 10.1002/jnr.21604
[58] Carlstrom L, Ke ZJ, Unnerstall JR, Cohen RS, Pandey SC. Estrogen modulation of the 
cyclic AMP response element-binding protein pathway—Effects of long-term and acute 
treatments. Neuroendocrinology. 2001;74:227-243. DOI: 10.1159/000054690
[59] Yune TY, Park HG, Lee JY, Oh TH. Estrogen-induced bcl-2 expression after spinal cord 
injury is mediated through phosphoinositide-3-kinase/Akt-dependent CREB activation. 
Journal of Neurotrauma. 2008;25:1121-1131. DOI: 10.1089/neu.2008.0544
[60] Manavathi B, Kumar R. Steering estrogen signals from the plasma membrane to the 
nucleus: Two sides of the coin. Journal of Cellular Physiology. 2006;207:594-604. DOI: 
10.1002/jcp.20551
[61] Simoncini T, Hafezl-Moghadam A, Brazil DP, Ley K, Chin WW, Liao JK. Interaction of 
oestrogen receptor with the regulatory subunit of phosphatidylinositol-3-OH kinase. 
Nature. 2000;407:538-541
[62] Malyala A, Zhang C, Bryant DN, Kelly MJ, Ronneklev OK. PI3K signaling effects in 
hypothalamic neurons mediated by estrogen. Journal of Comparative Neurology. 2008; 
506:895-911. DOI: 10.1002/cne.21584
17β-Estradiol as a Neuroprotective Agent
http://dx.doi.org/10.5772/intechopen.72682
35
[63] Coleman KM, Smith CL. Intracellular signaling pathways: Nongenomic actions of estro-
gens and ligand-independent activation of estrogen receptors. Frontiers in Bioscience. 
2001;6:D1379-D1391. DOI: 10.2741/Coleman
[64] Grissom EM, Daniel JM. Evidence for ligand-independent activation of hippocampal 
estrogen receptor-alpha by IGF-1 in hippocampus of ovariectomized rats. Endocrinology. 
2016;157:3149-3156. DOI: 10.1210/en.2016-1197
[65] Wang Q, Cao J, Hu F, RZ L, Wang J, Ding HX, Gao R, Xiao H. Effects of estradiol on 
voltage-gated sodium channels in mouse dorsal root ganglion neurons. Brain Research. 
2013;1512:2-8. DOI: 10.1016/j.brainres.2013.02.047
[66] Kow LM, Pataky S, Dupre C, Phan A, Martin-Alguacil N, Pfaff DW. Analyses of rapid 
estrogen actions on rat ventromedial hypothalamic neurons. Steroids. 2016;111:100-112. 
DOI: 10.1016/j.steroids.2016.03.010
[67] Yang S, Liu R, Perez EJ, Wen Y, Stevens SM Jr, Valencia T, Brun-Zinkernagel AM, Prokai L, 
Will Y, Dykens J, Koulen P, Simpkins JW. Mitochondrial localization of estrogen receptor 
beta. Proceedings of the National Academy of Sciences of the United States of America. 
2004;101:4130-4135. DOI: 10.1073/pnas.0306948101
[68] Susanne A, Victor MB, Beyer C. Estrogen and the regulation of mitochondrial struc-
ture and function in the brain. Journal of Steroid Biochemistry and Molecular Biology. 
2012;131:2-9. DOI: 10.1016/j.jsbmb.2012.01.012
[69] Velarde MC. Pleiotropic actions of estrogen: A mitochondrial matter. Physiological 
Genomics. 2013;46:103-109. DOI: 10.1152/physiolgenomics.00155.2012
[70] Jose Perez-Alvarez M, Wandosell F. Stroke and neuroinflamation: Role of sexual hor-
mones. Current Pharmaceutical Design. 2016;22:1334-1349. DOI: 10.2174/138161282210
160304112834
[71] Simon DW, McGeachy MJ, Bayir H, Clark RSB, Loane DJ, Kochanek PM. The far-reaching 
scope of neuroinflammation after traumatic brain injury. Nature Reviews Neurology. 
2017;11:171-191. DOI: 10.1038/nrneurol.2017.13
[72] Hong H, Kim B, Im HI. Pathophysiological role of neuroinflammation in neurodegen-
erative diseases and psychiatric disorders. International Neurology Journal. 2016;20:S2-
S7. DOI: 10.5213/inj.1632604.302
[73] Miller VM, Duckles SP. Vascular actions of estrogens: Functional implications. 
Physiological Reviews. 2008;60:210-241. DOI: 10.1124/pr.107.08002
[74] Duckles SP, Krause DN. Mechanisms of cerebrovascular protection: Oestrogen, 
inflammation and mitochondria. Acta Physiologica. 2011;203:149-154. DOI: 10.1111/ 
j.1748-1716.2010.02184.x
[75] Ospina JA, Brevig HN, Krause DN, Duckles SP. Estrogen suppresses IL-1 beta-medi-
ated induction of COX-2 pathway in rat cerebral blood vessels. American Journal of 
Physiology. 2004;286:H2010-H2019. DOI: 10.1152/ajpheart.00481.2003
Sex Hormones in Neurodegenerative Processes and Diseases36
[76] Stacey W, Bhave S, Uht RM. Mechanisms by which 17β-Estradiol (E2) suppress neuronal 
cox-2 gene expression. PLoS One. 2016;11:e0161430. DOI: 10.1371/journal.pone.0161430
[77] Pozzi S, Benedusi V, Maggi A, Vegeto E. Estrogen action in neuroprotection and brain 
inflammation. Annals of the New York Academy of Sciences. 2006;1089:302-323. DOI: 
10.1196/annals.1386.035
[78] Bruce-Keller AJ, Keeling JL, Keller JN, Huang FF, Camondola S, Mattson MP. 
Antiinflammatory effects of estrogen on microglial activation. Endocrinology. 2000; 
141:3646-3656. DOI: 10.1210/en.141.10.3646
[79] Ghisletti S, Meda C, Maggi A, Vegeto E. 17 β-estradiol inhibits inflammatory gene expres-
sion by controlling NF-κ B intracellular localization. Molecular and Cellular Biology. 
2005;25:2957-2968. DOI: 10.1128/MCB.25.8.2957-2968.2005
[80] Krishnan V, Khurana S, Tai TC. Oxidative stress in aging—Matters of the heart and 
mind. International Journal of Molecular Sciences. 2013;14:17897-17925. DOI: 10.3390/
ijms140917897
[81] Radi E, Formichi P, Battisti C, Federico A. Apoptosis and oxidative stress in neurode-
generative diseases. Journal of Alzheimer’s Disease. 2014;42:S125-S152. DOI: 10.3233/
JAD-132738
[82] Halliwell B, Gutteridge JMC. Lipid peroxidation, oxygen radicals, cell damage, and anti-
oxidant therapy. The Lancet. 1984;323:1396-1397. DOI: 10.1016/S0140-6736(84)91886-5
[83] Prokai L, Prokai-Tatrai K, Perjesi P, Simpkins JW. Mechanistic insights into the direct 
antioxidant effects of estrogens. Drug Development Research. 2005;66:118-125. DOI: 
10.1002/ddr.20050
[84] Borras C, Gambini J, Gomez-Cabrera MC, Sastre J, Pallardo FV, Mann GE, Vina J. 
17β-Oestradiol up-regulates longevity-related, antioxidant enzyme expression via 
the ERK1 and ERK2[MAPK]/NFκB cascade. Aging Cell. 2005;4:113-118. DOI: 10.1111/ 
j.1474-9726.2005.00151.x
[85] Stakhiv TM, Mesia-Vela S, Kauffman FC. Phase II antioxidant enzyme activities in 
brain of male and female ACI rats treated chronically with estradiol. Brain Research. 
2006;1104:80-91. DOI: 10.1016/j.brainres.2006.05.093
[86] Ruiz-Larrea B, Leal A, Martin C, Martinez R, Lacort M. Effects of estrogens on the redox 
chemistry of iron: A possible mechanism of the antioxidant action of estrogens. Steroids. 
1995;60:780-783. DOI: 10.1016/0039-128X(95)00119-B
[87] Behl C, Skutella T, Lezoualc’h F, Post A, Widmann M, Newton CJ, Holsboer F. 
Neuroprotection against oxidative stress by estrogens: Structure-activity relationship. 
Molecular Pharmacology. 1997;51:535-541
[88] Prokai L, Simpkins JW. Structure-nongenomic neuroprotection relationship of estrogens 
and estrogen-derived compounds. Pharmacology & Therapeutics. 2007;114:1-12. DOI: 
10.1016/j.pharmthera.2007.01.006
17β-Estradiol as a Neuroprotective Agent
http://dx.doi.org/10.5772/intechopen.72682
37
[89] Prokai L, Rivera-Portalatin NM, Prokai-Tatrai K. Quantitative structure-activity rela-
tionships predicting the antioxidant potency of 17β-estradiol-related polycyclic phenols 
to inhibit lipid peroxidation. International Journal of Molecular Sciences. 2013;14:1443-
1454. DOI: 10.3390/ijms14011443
[90] Kii N, Adachi N, Liu KY, Arai T. Acute effects of 17β-estradiol on oxidative stress in 
ischemic rat striatum. Journal of Neurosurgical Anesthesiology. 2005;17:27-32
[91] Caceres LG, Uran SL, Zubilete MAZ, Romero JI, Capani F, Guelman LR. An early treat-
ment with 17-beta-estradiol is neuroprotective against the long-term effects of neona-
tal ionizing radiation exposure. Journal of Neurochemistry. 2011;118:626-635. DOI: 
10.1111/j.1471-4159.2011.07334.x
[92] Prokai L, Oon SM, Prokai-Tatrai K, Abboud K, Simpkins JW. Synthesis and biological 
evaluation of 17β-alkoxyestra-1,3,5(10)-trienes as potential neuroprotectants against oxi-
dative stress. Journal of Medicinal Chemistry. 2001;44:110-114. DOI: 10.1021/jm000280t
[93] Prokai-Tatrai K, Prokai L, Simpkins JW, Jung ME. Phenolic compounds protect cultured 
hippocampal neurons against ethanol-withdrawal induced oxidative stress. International 
Journal of Molecular Sciences. 2009;10:1173-1187. DOI: 10.3390/ijms10041773
[94] Liang Y, Belford S, Tang F, Prokai L, Simpkins JW, Hughes JA. Membrane fluidity 
effects of estratrienes. Brain Research Bulletin. 2001;54:661-668. DOI: 10.1016/S0361- 
9230(01)00483-X
[95] Vedder H, Anthens N, Stumm G, Wurz C, Behl C, Krieg JC. Estrogen hormones reduce 
lipid peroxidation in cells and tissues of the central nervous system. Journal of Neuro-
chemistry. 1999;72:2531-2538. DOI: 10.1046/j.1471-4159.1999.0722531.x
[96] Packer JE, Slater TF, Wilson RL. Direct observation of a free radical interaction between 
vitamin E and vitamin C. Nature. 1978;278:737-738
[97] McCay PB, Brueggemann G, Lai EK, Powell SR. Evidence that α-tocopherol func-
tions cyclically to quench free radicals in hepatic microsomes. Annals of the New York 
Academy of Sciences. 1989;570:32-45. DOI: 10.1111/j.1749-6632.1989.tb14906.x
[98] Prokai L, Prokai-Tatrai K, Perjesi P, Zharikova AD, Perez EJ, Liu R, Simpkins JW. Quinol-
based cyclic antioxidant mechanism in estrogen neuroprotection. Proceedings of the 
National Academy of Sciences of the United States of America. 2003;100:11741-11746. 
DOI: 10.1073/pnas.2032621100
[99] Rivera-Portalatin NM, Vera-Serrano JL, Prokai-Tatrai K, Prokai L. Comparison of estro-
gen-derived ortho-quinone and para-quinol concerning induction of oxidative stress. 
Journal of Steroid Biochemistry and Molecular Biology. 2007;105:71-75. DOI: 10.1016/j.
jsbmb.2006.11.025
[100] Prokai-Tatrai K, Perjesi P, Rivera-Portalatin NM, Simpkins JW, Prokai L. Mechanistic 
investigations on the antioxidant action of a neuroprotective estrogen derivative. 
Steroids. 2008;73:280-288. DOI: 10.1016/j.steroids.2007.10.011
Sex Hormones in Neurodegenerative Processes and Diseases38
[101] Prokai L, Nguyen V, Szarka S, Garg P, Sabnis G, Bimonte-Nelson HA, McLaughlin KJ, 
Talboom JS, Conrad CD, Shughrue PJ, Gould TD, Brodie A, Merchenthaler I, Koulen P, 
Prokai-Tatrai K. The prodrug DHED selectively delivers 17β-estradiol to the 
brain for treating estrogen-responsive disorders. Science Translational Medicine. 
2015;7(297):297ra113. DOI: 10.1126/scitranslmed.aab1290
[102] Krishnamurthy K, Laskowitz DT. Chapter 5: Cellular and molecular mechanisms of 
secondary neuronal injury following traumatic brain injury. In: Laskowitz D, Grant G, 
editors. Translational Research in Traumatic Brain Injury. Boca Raton: CRC Press/
Taylor and Francis Group; 2016 Available from: https://www.ncbi.nlm.nih.gov/books/
NBK32671
[103] Diaz-Arrastia R, Kochanek PM, Bergold P, Kenney K, Marx CE, Grimes CJ, Loh LT, 
Adam LT, Oskvig D, Curley KC, Salzer W. Pharmacotherapy of traumatic brain 
injury: State of the science and the road forward: Report of the Department of Defense 
Neurotrauma Pharmacology Workgroup. Journal of Neurotrauma. 2014;31:135-158. 
DOI: 10.1089/neu.2013.3019
[104] Clark JH. A critique of Women’s health initiative studies (2002-2006). Nuclear Receptor 
Signaling. 2006;4:e023. DOI: 10.1621/nrs.04023
[105] Levy MJ, Boyne MT, Rogstad S, Skanchy DJ, Jiang X, Vidavsky IG. Marketplace analy-
sis of conjugated estrogens: Determining the consistently present steroidal content with 
LC-MS. AAPS Journal. 2015;17:1438-1445. DOI: 10.1208/s12248-015-9805-x
[106] Prokai-Tatrai K, Prokai L. Impact of metabolism on the safety of estrogen therapy. 
Annals of the New York Academy of Sciences. 2005;1052:243-257. DOI: 10.1196/
annals.1347.018
[107] Zhang F, Chen Y, Pisha E, Shen L, Xiong Y, van Breemen RB, Bolton JL. The major 
metabolite of equilin, 4-hydroxyequilin, autoxidizes to an o-quinone which isomer-
izes to the potent cytotoxin 4-hydroxyequilenin-o-quinone. Chemical Research in 
Toxicology. 1999;12:204-213. DOI: 10.1021/tx980217v
[108] Prokai L, Prokai-Tatrai K, Bodor N. Targeting drugs to the brain by redox chemi-
cal delivery systems. Medicinal Resesearch Reviews. 2000;20:367-416. DOI: 10.1002/ 
1098-1128(200009)20:5<367::AID-MED3>3.0.CO;2-P
[109] Sarkar DK, Friedman SJ, Yen SS, Frautschy SA. Chronic inhibition of hypothalamic-
pituitary-ovarian axis and body weight gain by brain-directed delivery of estradiol-17β 
in female rats. Neuroendocrinology. 1989;50:204-210. DOI: 10.1159/000125223
[110] Prokai-Tatrai K, Rivera-Portalatin NM, Rauniyar N, Prokai L. A facile microwave-
assisted synthesis of p-quinols by lead(IV)acetate oxidation. Letters in Organic Che-
mistry. 2007;4:265-267. DOI: 10.2174/157017807781024200
[111] Etgen AM, Jover-Mengual T, Zukina RS. Neuroprotective actions of estradiol and 
novel estrogen analogs in ischemia: Translational implications. Frontiers in Neuro-
endocrinology. 2011;32:336-352. DOI: 10.1016/j.yfrne.2010.12.005
17β-Estradiol as a Neuroprotective Agent
http://dx.doi.org/10.5772/intechopen.72682
39

